ClinicalTrials.gg
RecruitingNCT07817537Updated Sep 14, 2026

Evaluating the Effectiveness of Intramuscular Versus Intravenous Tranexamic Acid for Minimizing Blood Loss After Total Hip Arthroplasty: A Randomized Controlled Trial

An Early Phase 1 interventional study of Tranexamic Acid (TXA) intarmuscular and Tranexamic Acid (TXA) intravenous in Blood Loss After a Total Hip Replacement, sponsored by Alexandria University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Alexandria University · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2026, registered Jul 2026).
  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Intramuscular vs. Intravenous Tranexamic Acid for Total Hip Arthroplasty

02

Conditions studied

  • Blood Loss After a Total Hip Replacement
03

In context

Lead sponsor

Alexandria University is the lead sponsor of 607 studies on the registry; 142 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients aged 18 years and older.
  2. Scheduled to undergo elective primary total hip arthroplasty.
  3. Able to provide .

Exclusion criteria

Exclusion Criteria:

  • 1. History of renal failure or kidney transplant. 2. History of an arterial thromboembolic event (such as myocardial infarction or stroke) within the past year.

    3. Placement of an arterial stent within the past year. 4. History of deep venous thrombosis (DVT) or pulmonary embolism (PE). 5. Known to tranexamic acid. 6. Pregnancy or breastfeeding. 7. Refusal to participate or refusal to consent to receive blood products.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Intramuscular TXA

    Tranexamic acid 1 gram administered via deep intramuscular injection into the lateral thigh or deltoid muscle prior to surgery. Anesthesia maintained with a balanced inhalational technique (isoflurane 1-1.5% in oxygen-enriched air) and baseline fluid therapy 10 ml per kg per hour of lactated Ringer's solution).

    Drug: Tranexamic Acid (TXA) intarmuscular

  • Active comparator
    Intravenous TXA

    Tranexamic acid 1 gram administered intravenously over 10 minutes, following standard protocols, prior to surgery. Anesthesia maintained with a balanced inhalational technique (isoflurane 1-1.5% in oxygen-enriched air) and baseline fluid therapy 10 ml per kg per hour of lactated Ringer's solution).

    Drug: Tranexamic Acid (TXA) intravenous

Interventions

  • DrugTranexamic Acid (TXA) intarmuscular

    Tranexamic acid 1 gram administered via deep intramuscular injection into the lateral thigh or deltoid muscle prior to surgery.

  • Tranexamic acid 1 gram administered intravenously over 10 minutes, following standard protocols, prior to surgery.

06

What researchers measure

Primary outcomes

  1. Change of Hemoglobin Concentration

    Time frame: From baseline (preoperative) up to hospital discharge (typically 3-5 days postoperatively).

Secondary outcomes

  1. Postoperative Calculated Blood Loss

    Volume of total blood loss calculated as a function of patient characteristics (sex, height, weight) and perioperative hemoglobin balance using standard Gross and Nadler mathematical formulas.

    Time frame: From day 1 Up to hospital discharge.

  2. Postoperative Calculated Hemoglobin Loss

    Total mass of hemoglobin loss calculated based on patient baseline physical parameters and perioperative hemoglobin balance.

    Time frame: From day 1 Up to hospital discharge.

  3. Number of Blood Units Transfused

    The total cumulative units of blood products administered per patient.

    Time frame: From the start of surgery at day 1 up to hospital discharge.

  4. Blood Transfusion Rate

    The percentage/proportion of patients requiring allogeneic blood transfusion.

    Time frame: From day 1 at the start of surgery up to hospital discharge

  5. Length of Hospital Stay

    Total number of days from surgical admission to official hospital discharge

    Time frame: Up to 30 days postoperatively.

  6. Incidence of Thromboembolic Events

    Frequency of clinical or diagnostic thromboembolic complications (including deep venous thrombosis, pulmonary embolism, myocardial infarction, or stroke

    Time frame: Up to 30 days postoperatively.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2026
First posted
Sep 14, 2026
StartActual
Jan 15, 2026
Primary completionEst.
Jan 15, 2027
CompletionEst.
Mar 1, 2027
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07817537
Responsible party
Sponsor
First posted
Sep 14, 2026
Start date
Jan 15, 2026
Primary completion
Jan 15, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Sep 14, 2026

Study contacts

Tarek I Ismail
Contact
Drtarek.anesth@gmail.com
+201001467166

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion